CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 47 enrolled
Drug / intervention
Gum Arabicdietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02467257
NCT02467257Phase 2Completed
CompareCT.gov

Potential Role of Gum Arabic as Fetal Hemoglobin Agent in Sudanese Sickle Cell Anemia Patients

Al-Neelain University·interventional·Posted Jun 10, 2015·Updated Jun 10, 2015

In Brief

A Phase 2 clinical trial evaluating Gum Arabic for Sickle Cell Anemia. Completed, enrolled 47 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether Gum Arabic is effective as fetal hemoglobin inducing agent for sickle cell anemia patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSickle Cell Anemia
CountriesSudan
CollaboratorsMilitary hospital, Ministry of Higher Education and Scientific Research, Republic of Sudan

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 10, 2015
Enrollment StartApr 1, 2014
Primary CompletionJan 1, 2015
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 11.1 years ago

Interventions

Gum Arabicdietary

oral ingestion of 30 gram every day for 12 weeks